BioInsights - Automated and scalable closed-system platform for cell isolation and activation

Automated and scalable closed-system platform for cell isolation and activation

Cell & Gene Therapy Insights 2022; 8(8),1139;

DOI: 10.18609/cgti.2022.169

Published: 5 October 2022
FastFacts
Tom Mellody


Watch the video or read the poster to learn:

  • The importance of a scalable and robust cell isolation and bead removal in a closed, automated instrument
  • How to achieve >90% isolation efficiency of target cells with >95% purity with no effect on cell viability
  • The benefit of avoiding manual processing during cell therapy manufacturing, which can result in inconsistencies, contamination, and long throughput times

Tom Mellody studied biology and chemistry at the University of Buffalo. Since joining Thermo Fisher Scientific almost three years ago, Tom has been a member of the Cell Therapy R&D team where he focuses on end-to-end optimization of T cell workflows, from isolation to editing and process development, including downstream expansion across several different bioreactor platforms.